The PIONEER-HF study demonstrated that within eight weeks initiation of Entresto (sacubitril/valsartan) resulted in a significantly greater reduction in NT-proBNP concentration than enalapril therapy before discharge among patients who were stabilized after an event for acute decompensated heart failure (HFrEF). No significant differences were observed between the two groups regarding the pre-specified safety parameters.¹